Published in J Lipid Res on August 15, 2012
Novel gene-by-environment interactions: APOB and NPC1L1 variants affect the relationship between dietary and total plasma cholesterol. J Lipid Res (2013) 0.94
Pharmacogenetics of paraoxonase activity: elucidating the role of high-density lipoprotein in disease. Pharmacogenomics (2013) 0.91
HDL-3 is a superior predictor of carotid artery disease in a case-control cohort of 1725 participants. J Am Heart Assoc (2014) 0.87
Novel common and rare genetic determinants of paraoxonase activity: FTO, SERPINA12, and ITGAL. J Lipid Res (2012) 0.83
PLTP activity inversely correlates with CAAD: effects of PON1 enzyme activity and genetic variants on PLTP activity. J Lipid Res (2015) 0.81
Rare coding variation in paraoxonase-1 is associated with ischemic stroke in the NHLBI Exome Sequencing Project. J Lipid Res (2014) 0.80
Single nucleotide polymorphisms in CETP, SLC46A1, SLC19A1, CD36, BCMO1, APOA5, and ABCA1 are significant predictors of plasma HDL in healthy adults. Lipids Health Dis (2013) 0.80
Dietary fatty acid intake is associated with paraoxonase 1 activity in a cohort-based analysis of 1,548 subjects. Lipids Health Dis (2013) 0.79
Effects of dietary components on high-density lipoprotein measures in a cohort of 1,566 participants. Nutr Metab (Lond) (2014) 0.77
Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem (1972) 95.79
Reproducibility and validity of an expanded self-administered semiquantitative food frequency questionnaire among male health professionals. Am J Epidemiol (1992) 17.17
Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med (2011) 15.30
Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet (2012) 12.10
Dextran sulfate-Mg2+ precipitation procedure for quantitation of high-density-lipoprotein cholesterol. Clin Chem (1982) 9.77
Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature (1998) 3.84
Enzymatic methods for quantification of lipoprotein lipids. Methods Enzymol (1986) 3.31
Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein. J Clin Invest (1995) 3.23
Oral administration of an Apo A-I mimetic Peptide synthesized from D-amino acids dramatically reduces atherosclerosis in mice independent of plasma cholesterol. Circulation (2002) 2.91
Cholesterol and heart disease in older persons and women. Review of an NHLBI workshop. Ann Epidemiol (1994) 2.50
Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase. Atherosclerosis (1993) 2.48
Mechanisms underlying adverse effects of HDL on eNOS-activating pathways in patients with coronary artery disease. J Clin Invest (2011) 2.37
Combined serum paraoxonase knockout/apolipoprotein E knockout mice exhibit increased lipoprotein oxidation and atherosclerosis. J Biol Chem (2000) 2.02
Paraoxonase activity, but not haplotype utilizing the linkage disequilibrium structure, predicts vascular disease. Arterioscler Thromb Vasc Biol (2003) 2.01
Alcohol consumption and risk of ischemic stroke: The Framingham Study. Stroke (2002) 1.97
Paraoxonase (PON1) phenotype is a better predictor of vascular disease than is PON1(192) or PON1(55) genotype. Arterioscler Thromb Vasc Biol (2000) 1.94
Vitamin C and E intake is associated with increased paraoxonase activity. Arterioscler Thromb Vasc Biol (2002) 1.93
Effects of 5' regulatory-region polymorphisms on paraoxonase-gene (PON1) expression. Am J Hum Genet (2001) 1.85
Assessing low levels of high-density lipoprotein cholesterol as a risk factor in coronary heart disease: a working group report and update. J Am Coll Cardiol (2004) 1.84
Human and murine paraoxonase 1 are host modulators of Pseudomonas aeruginosa quorum-sensing. FEMS Microbiol Lett (2005) 1.81
Effectiveness of various mailing strategies among nonrespondents in a prospective cohort study. Am J Epidemiol (1990) 1.78
Determination of paraoxonase 1 status without the use of toxic organophosphate substrates. Circ Cardiovasc Genet (2008) 1.76
PON1 status of farmworker mothers and children as a predictor of organophosphate sensitivity. Pharmacogenet Genomics (2006) 1.75
LCAT, HDL cholesterol and ischemic cardiovascular disease: a Mendelian randomization study of HDL cholesterol in 54,500 individuals. J Clin Endocrinol Metab (2011) 1.65
Meta-analysis of folic acid supplementation trials on risk of cardiovascular disease and risk interaction with baseline homocysteine levels. Am J Cardiol (2010) 1.64
Polymorphisms in the human paraoxonase (PON1) promoter. Pharmacogenetics (2001) 1.46
Serum paraoxonase after myocardial infarction. Arterioscler Thromb Vasc Biol (1999) 1.42
Serum paraoxonase (PON1) 55 and 192 polymorphism and paraoxonase activity and concentration in non-insulin dependent diabetes mellitus. Atherosclerosis (1998) 1.36
Dietary intakes of zinc and heme iron from red meat, but not from other sources, are associated with greater risk of metabolic syndrome and cardiovascular disease. J Nutr (2012) 1.36
Serum paraoxonase and its influence on paraoxon and chlorpyrifos-oxon toxicity in rats. Toxicol Appl Pharmacol (1990) 1.32
Effect of the dietary fat quality on insulin sensitivity. Br J Nutr (2008) 1.29
Drosophila are protected from Pseudomonas aeruginosa lethality by transgenic expression of paraoxonase-1. J Clin Invest (2008) 1.22
Smoking is associated with reduced serum paraoxonase activity and concentration in patients with coronary artery disease. Circulation (2000) 1.22
Paraoxonase 1 (PON1) status and substrate hydrolysis. Toxicol Appl Pharmacol (2008) 1.21
Paraoxonase and coronary heart disease. Atheroscler Suppl (2002) 1.14
Novel paraoxonase (PON1) nonsense and missense mutations predicted by functional genomic assay of PON1 status. Pharmacogenetics (2003) 1.14
Daily moderate alcohol consumption increases serum paraoxonase activity; a diet-controlled, randomised intervention study in middle-aged men. Atherosclerosis (1999) 1.12
Consumption of wonderful variety pomegranate juice and extract by diabetic patients increases paraoxonase 1 association with high-density lipoprotein and stimulates its catalytic activities. J Agric Food Chem (2008) 1.09
Precipitation methods for quantification of lipoproteins. Methods Enzymol (1986) 1.08
Simvastatin modulates expression of the PON1 gene and increases serum paraoxonase: a role for sterol regulatory element-binding protein-2. Arterioscler Thromb Vasc Biol (2003) 1.04
Genetic polymorphism of paraoxonase 1 (PON1) and susceptibility to Parkinson's disease. Brain Res (1998) 1.03
Analysis of recently identified dyslipidemia alleles reveals two loci that contribute to risk for carotid artery disease. Lipids Health Dis (2009) 1.03
Effect of simvastatin therapy on paraoxonase activity and related lipoproteins in familial hypercholesterolemic patients. Arterioscler Thromb Vasc Biol (2000) 1.03
Inhibition of paraoxonase activity in human liver microsomes by exposure to EDTA, metals and mercurials. Chem Biol Interact (1997) 1.02
Kinetics of HDL cholesterol and paraoxonase activity in moderate alcohol consumers. Alcohol Clin Exp Res (2002) 1.00
HDL metabolism and CETP inhibition. Cardiol Rev (2008) 1.00
Reduced postprandial serum paraoxonase activity after a meal rich in used cooking fat. Arterioscler Thromb Vasc Biol (1999) 0.99
Paraoxonase 1 status as a risk factor for disease or exposure. Adv Exp Med Biol (2010) 0.99
Roles of Sp1 and protein kinase C in regulation of human serum paraoxonase 1 (PON1) gene transcription in HepG2 cells. Atherosclerosis (2004) 0.98
Association study of detoxification genes in age related macular degeneration. Br J Ophthalmol (2005) 0.97
Alcohol and the risk of myocardial infarction. Basic Res Cardiol (2001) 0.97
Decreased serum paraoxonase 1 activity and increased serum homocysteine and malondialdehyde levels in age-related macular degeneration. Tohoku J Exp Med (2009) 0.97
The antioxidant HDL-associated paraoxonase-1 (PON1) attenuates diabetes development and stimulates β-cell insulin release. Atherosclerosis (2011) 0.97
Reduced paraoxonase1 activity is a risk for atherosclerosis in patients with systemic lupus erythematosus. Ann N Y Acad Sci (2007) 0.96
Polymorphisms in three obesity-related genes (LEP, LEPR, and PON1) and breast cancer risk: a meta-analysis. Tumour Biol (2011) 0.96
Paraoxonase protection of LDL against peroxidation is independent of its esterase activity towards paraoxon and is unaffected by the Q-->R genetic polymorphism. J Lipid Res (1999) 0.95
Light, but not heavy alcohol drinking, stimulates paraoxonase by upregulating liver mRNA in rats and humans. Metabolism (2003) 0.94
Interaction between the Gln-Arg 192 variants of the paraoxonase gene and oleic acid intake as a determinant of high-density lipoprotein cholesterol and paraoxonase activity. Eur J Pharmacol (2001) 0.93
TagSNP analyses of the PON gene cluster: effects on PON1 activity, LDL oxidative susceptibility, and vascular disease. J Lipid Res (2006) 0.92
Paraoxonase 1 Met--Leu 54 polymorphism is associated with Parkinson's disease. J Neurol Sci (2001) 0.91
Determinants of variation in serum paraoxonase enzyme activity in baboons. J Lipid Res (2005) 0.91
The effect of meals rich in thermally stressed olive and safflower oils on postprandial serum paraoxonase activity in patients with diabetes. Eur J Clin Nutr (2001) 0.91
Serum paraoxonase-1 in chronic alcoholics: relationship with liver disease. Clin Biochem (2007) 0.90
Assessment of paraoxonase and arylesterase activities in patients with iron deficiency anemia. Atherosclerosis (2006) 0.90
Paraoxonase 1 genetic polymorphisms and susceptibility to breast cancer: a meta-analysis. Cancer Epidemiol (2011) 0.90
Further evidence for an association of the paraoxonase 1 (PON1) Met-54 allele with Parkinson's disease. Mov Disord (2002) 0.89
Genetic association study of age-related macular degeneration in the Spanish population. Acta Ophthalmol (2010) 0.88
Relationship of serum paraoxonase 1 activity and paraoxonase 1 genotype to risk of systemic lupus erythematosus. Arthritis Rheum (2006) 0.88
Serum paraoxonase 1 activity and lipid peroxidation levels in patients with age-related macular degeneration. Ophthalmologica (2006) 0.88
Alpha-tocopherol supplementation prevents the exercise-induced reduction of serum paraoxonase 1/arylesterase activities in healthy individuals. Eur J Clin Nutr (2007) 0.87
Alcohol consumption and risk of lung cancer: the Framingham Study. J Natl Cancer Inst (2002) 0.87
Additional Common Polymorphisms in the PON Gene Cluster Predict PON1 Activity but Not Vascular Disease. J Lipids (2012) 0.87
Evidence for a paraoxonase-independent inhibition of low-density lipoprotein oxidation by high-density lipoprotein. Atherosclerosis (1997) 0.86
Association of the M55L and Q192R paraoxonase gene polymorphisms with age-related macular degeneration. Am J Ophthalmol (2004) 0.86
Oxidative inactivation of lactonase activity of purified human paraoxonase 1 (PON1). Biochim Biophys Acta (2008) 0.86
Association analysis of PON2 genetic variants with serum paraoxonase activity and systemic lupus erythematosus. BMC Med Genet (2011) 0.85
Rosiglitazone modulates fasting and post-prandial paraoxonase 1 activity in type 2 diabetic patients. Clin Exp Pharmacol Physiol (2006) 0.84
Purification human PON1Q192 and PON1R192 isoenzymes by hydrophobic interaction chromatography and investigation of the inhibition by metals. J Chromatogr B Analyt Technol Biomed Life Sci (2008) 0.82
Paraoxonase (PON1 and PON3) Polymorphisms: Impact on Liver Expression and Atorvastatin-Lactone Hydrolysis. Front Pharmacol (2011) 0.82
Protective effect of paraoxonase 1 gene variant Gln192Arg in age-related macular degeneration. Am J Ophthalmol (2009) 0.82
Serum paraoxonase phenotype distribution in exudative age-related macular degeneration and its relationship to homocysteine and oxidized low-density lipoprotein. Retina (2012) 0.82
The differentiating effect of glimepiride and glibenclamide on paraoxonase 1 and platelet-activating factor acetylohydrolase activity. Life Sci (2010) 0.81
Effect of metal ions and calcium on purified PON1 and PON3 from rat liver. Chem Biol Interact (2007) 0.81
Imbalance in superoxide dismutase/thioredoxin reductase activities in hypercholesterolemic subjects: relationship with low density lipoprotein oxidation. Lipids Health Dis (2012) 0.80
Paraoxonase and arylesterase activities in children with iron deficiency anemia and vitamin B12 deficiency anemia. Pediatr Hematol Oncol (2012) 0.80
Delayed loss of cholesterol from a localized lipoprotein depot in apolipoprotein A-I-deficient mice. Proc Natl Acad Sci U S A (1997) 0.79
Purification of PON1 from human serum and assessment of enzyme kinetics against metal toxicity. Biol Trace Elem Res (2009) 0.78
Increased oxidized-LDL levels and arylesterase activity/HDL ratio in ESRD patients treated with hemodialysis. Clin Invest Med (2012) 0.78
Paraoxonase activity in athletes with depleted iron stores and iron-deficient erythropoiesis. Clin Biochem (2010) 0.76
Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat Genet (2011) 10.07
The eMERGE Network: a consortium of biorepositories linked to electronic medical records data for conducting genomic studies. BMC Med Genomics (2011) 9.20
Ethical and practical guidelines for reporting genetic research results to study participants: updated guidelines from a National Heart, Lung, and Blood Institute working group. Circ Cardiovasc Genet (2010) 6.74
Loss-of-function mutations in APOC3, triglycerides, and coronary disease. N Engl J Med (2014) 5.47
Systematic comparison of phenome-wide association study of electronic medical record data and genome-wide association study data. Nat Biotechnol (2013) 4.85
Reporting genetic results in research studies: summary and recommendations of an NHLBI working group. Am J Med Genet A (2006) 4.56
The Electronic Medical Records and Genomics (eMERGE) Network: past, present, and future. Genet Med (2013) 4.37
Use of diverse electronic medical record systems to identify genetic risk for type 2 diabetes within a genome-wide association study. J Am Med Inform Assoc (2011) 4.20
Actionable, pathogenic incidental findings in 1,000 participants' exomes. Am J Hum Genet (2013) 4.06
Variants near FOXE1 are associated with hypothyroidism and other thyroid conditions: using electronic medical records for genome- and phenome-wide studies. Am J Hum Genet (2011) 3.85
Detectable clonal mosaicism from birth to old age and its relationship to cancer. Nat Genet (2012) 3.68
Association of in utero organophosphate pesticide exposure and fetal growth and length of gestation in an agricultural population. Environ Health Perspect (2004) 3.66
Genomic research and wide data sharing: views of prospective participants. Genet Med (2010) 3.45
Return of individual research results from genome-wide association studies: experience of the Electronic Medical Records and Genomics (eMERGE) Network. Genet Med (2012) 3.29
Glad you asked: participants' opinions of re-consent for dbGap data submission. J Empir Res Hum Res Ethics (2010) 3.29
The G protein-coupled receptor repertoires of human and mouse. Proc Natl Acad Sci U S A (2003) 3.24
Recommendations for returning genomic incidental findings? We need to talk! Genet Med (2013) 3.23
Toll-like receptor 1 polymorphisms affect innate immune responses and outcomes in sepsis. Am J Respir Crit Care Med (2008) 2.64
National Institutes of Health State-of-the-Science Conference Statement: Family History and Improving Health. Ann Intern Med (2009) 2.58
Large-scale gene-centric meta-analysis across 39 studies identifies type 2 diabetes loci. Am J Hum Genet (2012) 2.53
Association between in utero organophosphate pesticide exposure and abnormal reflexes in neonates. Neurotoxicology (2005) 2.49
Presence of intraplaque hemorrhage stimulates progression of carotid atherosclerotic plaques: a high-resolution magnetic resonance imaging study. Circulation (2005) 2.36
Apolipoprotein E genotype and neurodevelopmental sequelae of infant cardiac surgery. J Thorac Cardiovasc Surg (2003) 2.25
Periventricular leukomalacia is common after neonatal cardiac surgery. J Thorac Cardiovasc Surg (2004) 2.19
Meta-analysis of Dense Genecentric Association Studies Reveals Common and Uncommon Variants Associated with Height. Am J Hum Genet (2010) 2.15
The FDA and genomic tests--getting regulation right. N Engl J Med (2015) 2.09
Processes and preliminary outputs for identification of actionable genes as incidental findings in genomic sequence data in the Clinical Sequencing Exploratory Research Consortium. Genet Med (2013) 2.08
Novel late-onset Alzheimer disease loci variants associate with brain gene expression. Neurology (2012) 2.08
Genome- and phenome-wide analyses of cardiac conduction identifies markers of arrhythmia risk. Circulation (2013) 2.06
Paraoxonase activity, but not haplotype utilizing the linkage disequilibrium structure, predicts vascular disease. Arterioscler Thromb Vasc Biol (2003) 2.01
Genetic variants associated with the white blood cell count in 13,923 subjects in the eMERGE Network. Hum Genet (2011) 2.00
ColoSeq provides comprehensive lynch and polyposis syndrome mutational analysis using massively parallel sequencing. J Mol Diagn (2012) 1.99
Large-scale gene-centric meta-analysis across 32 studies identifies multiple lipid loci. Am J Hum Genet (2012) 1.96
A combined genomewide linkage scan of 1,233 families for prostate cancer-susceptibility genes conducted by the international consortium for prostate cancer genetics. Am J Hum Genet (2005) 1.96
Technical desiderata for the integration of genomic data into Electronic Health Records. J Biomed Inform (2011) 1.96
Vitamin C and E intake is associated with increased paraoxonase activity. Arterioscler Thromb Vasc Biol (2002) 1.93
Perioperative stroke in infants undergoing open heart operations for congenital heart disease. Ann Thorac Surg (2009) 1.82
Modulation of paraoxonase (PON1) activity. Biochem Pharmacol (2005) 1.80
Determination of paraoxonase 1 status without the use of toxic organophosphate substrates. Circ Cardiovasc Genet (2008) 1.76
PON1 status of farmworker mothers and children as a predictor of organophosphate sensitivity. Pharmacogenet Genomics (2006) 1.75
Arterial remodeling in [corrected] subclinical carotid artery disease. JACC Cardiovasc Imaging (2009) 1.74
Patient characteristics are important determinants of neurodevelopmental outcome at one year of age after neonatal and infant cardiac surgery. J Thorac Cardiovasc Surg (2007) 1.71
Complement receptor 1 gene variants are associated with erythrocyte sedimentation rate. Am J Hum Genet (2011) 1.66
The relationship of postoperative electrographic seizures to neurodevelopmental outcome at 1 year of age after neonatal and infant cardiac surgery. J Thorac Cardiovasc Surg (2005) 1.65
Neurodevelopmental outcomes after staged palliation for hypoplastic left heart syndrome. Pediatrics (2008) 1.55
Functional genomic of the paraoxonase (PON1) polymorphisms: effects on pesticide sensitivity, cardiovascular disease, and drug metabolism. Annu Rev Med (2001) 1.51
Postoperative electroencephalographic seizures are associated with deficits in executive function and social behaviors at 4 years of age following cardiac surgery in infancy. J Thorac Cardiovasc Surg (2013) 1.50
Informed Consent in Genome-Scale Research: What Do Prospective Participants Think? AJOB Prim Res (2012) 1.50
Predictors of carotid atherosclerotic plaque progression as measured by noninvasive magnetic resonance imaging. Atherosclerosis (2006) 1.48
A genome- and phenome-wide association study to identify genetic variants influencing platelet count and volume and their pleiotropic effects. Hum Genet (2013) 1.47
Increasing duration of deep hypothermic circulatory arrest is associated with an increased incidence of postoperative electroencephalographic seizures. J Thorac Cardiovasc Surg (2005) 1.45
Measurement of paraoxonase (PON1) status as a potential biomarker of susceptibility to organophosphate toxicity. Clin Chim Acta (2005) 1.42
Leveraging the electronic health record to implement genomic medicine. Genet Med (2012) 1.42
Expression of human paraoxonase (PON1) during development. Pharmacogenetics (2003) 1.40
Genome-wide association study of plasma lipoprotein(a) levels identifies multiple genes on chromosome 6q. J Lipid Res (2009) 1.34
Follow-up of carriers of BRCA1 and BRCA2 variants of unknown significance: variant reclassification and surgical decisions. Genet Med (2011) 1.32
Polymorphisms of the IL1-receptor antagonist gene (IL1RN) are associated with multiple markers of systemic inflammation. Arterioscler Thromb Vasc Biol (2008) 1.32
Apolipoprotein E genotype modifies the risk of behavior problems after infant cardiac surgery. Pediatrics (2009) 1.30
Toxicity of chlorpyrifos and chlorpyrifos oxon in a transgenic mouse model of the human paraoxonase (PON1) Q192R polymorphism. Pharmacogenet Genomics (2005) 1.30
Loci influencing blood pressure identified using a cardiovascular gene-centric array. Hum Mol Genet (2013) 1.27
WNT1 mutations in families affected by moderately severe and progressive recessive osteogenesis imperfecta. Am J Hum Genet (2013) 1.27
Pitfalls of merging GWAS data: lessons learned in the eMERGE network and quality control procedures to maintain high data quality. Genet Epidemiol (2011) 1.26
Paraoxonase (PON 1) as a biomarker of susceptibility for organophosphate toxicity. Biomarkers (2003) 1.25
Is cardiac diagnosis a predictor of neurodevelopmental outcome after cardiac surgery in infancy? J Thorac Cardiovasc Surg (2010) 1.24
Engineered recombinant human paraoxonase 1 (rHuPON1) purified from Escherichia coli protects against organophosphate poisoning. Proc Natl Acad Sci U S A (2008) 1.24
Paraoxonase 1 (PON1) status and substrate hydrolysis. Toxicol Appl Pharmacol (2008) 1.21
CLIA-tested genetic variants on commercial SNP arrays: potential for incidental findings in genome-wide association studies. Genet Med (2010) 1.21
Paraoxonase gene mutations in amyotrophic lateral sclerosis. Ann Neurol (2010) 1.20
Predictors of impaired neurodevelopmental outcomes at one year of age after infant cardiac surgery. Eur J Cardiothorac Surg (2009) 1.17
Return of incidental findings in genomic medicine: measuring what patients value--development of an instrument to measure preferences for information from next-generation testing (IMPRINT). Genet Med (2013) 1.16
Return of results: ethical and legal distinctions between research and clinical care. Am J Med Genet C Semin Med Genet (2014) 1.16
Serum cholinesterase inhibition in relation to paraoxonase-1 (PON1) status among organophosphate-exposed agricultural pesticide handlers. Environ Health Perspect (2009) 1.14
Pharmacological and dietary modulators of paraoxonase 1 (PON1) activity and expression: the hunt goes on. Biochem Pharmacol (2010) 1.14
Multiple genome-wide analyses of smoking behavior in the Framingham Heart Study. BMC Genet (2003) 1.14
Novel paraoxonase (PON1) nonsense and missense mutations predicted by functional genomic assay of PON1 status. Pharmacogenetics (2003) 1.14
Genomic scan of 254 hereditary prostate cancer families. Prostate (2003) 1.14
High density GWAS for LDL cholesterol in African Americans using electronic medical records reveals a strong protective variant in APOE. Clin Transl Sci (2012) 1.13
Heritability of longitudinal measures of body mass index and lipid and lipoprotein levels in aging twins. Twin Res Hum Genet (2007) 1.12
Surface plasmon resonance detection using antibody-linked magnetic nanoparticles for analyte capture, purification, concentration, and signal amplification. Anal Chem (2009) 1.11
Genetic factors are important determinants of neurodevelopmental outcome after repair of tetralogy of Fallot. J Thorac Cardiovasc Surg (2008) 1.10
Identifying patients at high risk of a cardiovascular event in the near future: current status and future directions: report of a national heart, lung, and blood institute working group. Circulation (2010) 1.07
Detection of Staphylococcus aureus enterotoxin B at femtomolar levels with a miniature integrated two-channel surface plasmon resonance (SPR) sensor. Biosens Bioelectron (2002) 1.06
Exome sequencing reveals novel rare variants in the ryanodine receptor and calcium channel genes in malignant hyperthermia families. Anesthesiology (2013) 1.06
Paraoxonase 1 (PON1) modulates the toxicity of mixed organophosphorus compounds. Toxicol Appl Pharmacol (2009) 1.06
The correlation of paraoxonase (PON1) activity with lipid and lipoprotein levels differs with vascular disease status. J Lipid Res (2005) 1.06